CA2699856C - Improved methylation detection - Google Patents

Improved methylation detection Download PDF

Info

Publication number
CA2699856C
CA2699856C CA2699856A CA2699856A CA2699856C CA 2699856 C CA2699856 C CA 2699856C CA 2699856 A CA2699856 A CA 2699856A CA 2699856 A CA2699856 A CA 2699856A CA 2699856 C CA2699856 C CA 2699856C
Authority
CA
Canada
Prior art keywords
methylated
gene
moiety
amplification
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2699856A
Other languages
English (en)
French (fr)
Other versions
CA2699856A1 (en
Inventor
Ilse Vlassenbroeck
Katja Bierau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MDxHealth SA
Original Assignee
MDxHealth SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDxHealth SA filed Critical MDxHealth SA
Publication of CA2699856A1 publication Critical patent/CA2699856A1/en
Application granted granted Critical
Publication of CA2699856C publication Critical patent/CA2699856C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/30—Oligonucleotides characterised by their secondary structure
    • C12Q2525/301—Hairpin oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10—Detection mode being characterised by the assay principle
    • C12Q2565/101—Interaction between at least two labels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2699856A 2007-09-17 2008-09-17 Improved methylation detection Active CA2699856C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96012807P 2007-09-17 2007-09-17
US60/960,128 2007-09-17
PCT/GB2008/003145 WO2009037441A1 (en) 2007-09-17 2008-09-17 Improved methylation detection

Publications (2)

Publication Number Publication Date
CA2699856A1 CA2699856A1 (en) 2009-03-26
CA2699856C true CA2699856C (en) 2019-08-20

Family

ID=40239643

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2699856A Active CA2699856C (en) 2007-09-17 2008-09-17 Improved methylation detection
CA2699853A Abandoned CA2699853A1 (en) 2007-09-17 2008-09-17 Improved detection of mage-a expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2699853A Abandoned CA2699853A1 (en) 2007-09-17 2008-09-17 Improved detection of mage-a expression

Country Status (18)

Country Link
US (4) US9050280B2 (https=)
EP (2) EP2201131B8 (https=)
JP (1) JP5406839B2 (https=)
KR (1) KR20100085917A (https=)
CN (1) CN101932723B (https=)
AU (1) AU2008300397A1 (https=)
BR (1) BRPI0817008A2 (https=)
CA (2) CA2699856C (https=)
CO (1) CO6260156A2 (https=)
CR (1) CR11504A (https=)
DO (1) DOP2010000076A (https=)
EA (1) EA017879B1 (https=)
IL (1) IL204525A0 (https=)
MA (1) MA31753B1 (https=)
MX (1) MX2010002965A (https=)
NZ (2) NZ583796A (https=)
WO (2) WO2009037441A1 (https=)
ZA (1) ZA201001878B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037128A2 (en) * 2010-09-14 2012-03-22 The University Of North Carolina At Chapel Hill Methods and kits for detecting melanoma
WO2012129488A2 (en) * 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
EP4570924A3 (en) * 2013-01-24 2025-09-03 California Institute of Technology Chromophore-based characterization and detection methods
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
GB2550712B (en) * 2015-02-26 2021-01-13 Hitachi High Tech Corp Method for constructing hairpin-containing nucleic acid molecules for nanopore sequencing
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
CN105100961B (zh) * 2015-07-23 2018-03-13 华为技术有限公司 视频缩略图生成方法及生成装置
CN114574585A (zh) 2015-08-31 2022-06-03 梅约医药教育及研究基金会 检测胃肿瘤
DE102016005947B3 (de) 2016-05-16 2017-06-08 Dimo Dietrich Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
US10294518B2 (en) 2016-09-16 2019-05-21 Fluxion Biosciences, Inc. Methods and systems for ultra-sensitive detection of genomic alterations
US20200010907A1 (en) 2017-03-17 2020-01-09 Mdxhealth Sa Mgmt epigenetic deep-sequencing assay
US20180271710A1 (en) * 2017-03-22 2018-09-27 Bragi GmbH Wireless earpiece for tinnitus therapy
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
US11441182B2 (en) * 2018-08-08 2022-09-13 Virginia Commonwealth University Multiplexed and recyclable single-molecule sensors for quantitative analysis of nucleic-acid biomarkers
CN109540856B (zh) * 2018-11-08 2022-01-28 南京师范大学 一种基于荧光共振能量转移检测不同亚型乳腺癌细胞的试剂
CN111551978B (zh) * 2020-05-08 2022-09-27 中国辐射防护研究院 一种放射性土壤样品采样过程不确定度的评定方法
WO2023108145A1 (en) * 2021-12-10 2023-06-15 Nuprobe Usa, Inc. Universal probes for amplification and detection of nucleic acids
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
WO1989001050A1 (en) 1987-07-31 1989-02-09 The Board Of Trustees Of The Leland Stanford Junior University Selective amplification of target polynucleotide sequences
CA2005589C (en) 1988-12-16 2001-02-06 Akzo Nobel Nv Self-sustained, sequence replication system
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6117635A (en) * 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
US6768000B1 (en) * 1998-06-12 2004-07-27 Intergen Company Multi-fluorescent hairpin energy transfer oligonucleotides
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US20040033490A1 (en) * 2000-03-31 2004-02-19 Laird Peter W. Epigenetic sequences for esophageal adenocarcinoma
WO2002082086A2 (en) 2001-03-15 2002-10-17 Jacques Schrenzel Detection of methicillin-resistant staphylococcus aureus (mrsa)
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
DE60234386D1 (de) 2002-02-04 2009-12-24 Corixa Corp Neue immuneffektor-verbindungen
DE10215770A1 (de) * 2002-04-10 2003-10-30 Michael Giesing Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
WO2004087957A2 (en) * 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
US7881873B2 (en) * 2003-04-29 2011-02-01 The Jackson Laboratory Systems and methods for statistical genomic DNA based analysis and evaluation
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
DE10338308B4 (de) * 2003-08-15 2006-10-19 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierungen in DNA
US8062849B2 (en) * 2003-10-28 2011-11-22 The Johns Hopkins University Quantitative multiplex methylation-specific PCR
US20050130170A1 (en) * 2003-12-16 2005-06-16 Jeanne Harvey Identification and verification of methylation marker sequences
WO2006040187A2 (en) * 2004-10-11 2006-04-20 Epigenomics Ag A method for the carry-over protection in dna amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids
US20070059753A1 (en) * 2005-09-15 2007-03-15 Tatiana Vener Detecting gene methylation
GB0612342D0 (en) 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700374D0 (en) * 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
US8911937B2 (en) * 2007-07-19 2014-12-16 Brainreader Aps Method for detecting methylation status by using methylation-independent primers

Also Published As

Publication number Publication date
US20130302363A1 (en) 2013-11-14
NZ596545A (en) 2013-05-31
DOP2010000076A (es) 2010-08-15
EP2201131B1 (en) 2014-11-05
CA2699853A1 (en) 2009-03-26
BRPI0817008A2 (pt) 2017-05-16
US8481700B2 (en) 2013-07-09
US20160032368A1 (en) 2016-02-04
AU2008300397A1 (en) 2009-03-26
CA2699856A1 (en) 2009-03-26
CR11504A (es) 2011-05-10
ZA201001878B (en) 2011-05-25
US20100280105A1 (en) 2010-11-04
EA201000334A1 (ru) 2011-02-28
WO2009037438A1 (en) 2009-03-26
WO2009037438A8 (en) 2010-04-15
EP2201131B8 (en) 2014-12-10
US20110287416A1 (en) 2011-11-24
MX2010002965A (es) 2010-09-14
US10053724B2 (en) 2018-08-21
IL204525A0 (en) 2010-11-30
NZ583796A (en) 2011-12-22
US9050280B2 (en) 2015-06-09
KR20100085917A (ko) 2010-07-29
JP5406839B2 (ja) 2014-02-05
EA017879B1 (ru) 2013-03-29
MA31753B1 (fr) 2010-10-01
EP2198045A1 (en) 2010-06-23
CO6260156A2 (es) 2011-03-22
CN101932723A (zh) 2010-12-29
EP2201131A1 (en) 2010-06-30
JP2010538633A (ja) 2010-12-16
WO2009037441A1 (en) 2009-03-26
CN101932723B (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
CA2699856C (en) Improved methylation detection
CA2437044C (en) Method of determining a chemotherapeutic regimen based on ercc1 expression
US20190048422A1 (en) Compositions and methods for detecting and diagnosing neoplasia
ES2829616T3 (es) Procedimiento para la determinación de una mutación en ADN genómico, uso del procedimiento y kit para la realización del procedimiento
US10697021B2 (en) Methods of detecting breast cancer brain metastasis with genomic and epigenomic biomarkers
AU2002249768A1 (en) Method of determining a chemotherapeutic regimen based on ERCC1 expression
US10329621B2 (en) DNA methylation markers and methods of use
WO2011112880A2 (en) Hypermethylation biomarkers for detection of head and neck squamous cell cancer
WO2016168174A1 (en) Predicting the occurrence of metastatic cancer using epigenomic biomarkers and non-invasive methodologies
EP3720974A1 (en) Method for screening a subject for a cancer
Parrella et al. High specificity of quantitative methylation‐specific PCR analysis for MGMT promoter hypermethylation detection in gliomas
WO2023236201A1 (en) Methods, compositions, and kits for detecting malignant lung nodules and lung cancer
US11840738B2 (en) Method for determining risk of urothelial carcinoma
Chen et al. Hypermethylation of the pl5INK4B gene in acute leukemia and myelodysplastic syndromes
Tomita et al. Development of canine X-chromosome inactivation pattern analysis for the detection of cell clonality by incorporating the examination of the SLIT and NTRK-like family member 4 (SLITRK4) gene
US20090275632A1 (en) Methods of diagnosis and treatment
EP4526471A1 (en) Dna repair signature and prediction of response following cancer therapy
EP2406393B1 (en) Novel markers for bladder cancer detection
US20110159504A1 (en) Methylation markers for sensitivity to microtube based therapies and methods of use
CN120272592A (zh) 一种用于检测乳腺癌甲基化标志物的试剂盒及其应用
高瀬貴章 Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method
Parrella et al. Research Article High Specificity of Quantitative Methylation-Specific PCR Analysis for MGMT Promoter Hypermethylation Detection in Gliomas

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916